<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Neurol.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Neurology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Neurol.</abbrev-journal-title>
</journal-title-group>
<issn pub-type="epub">1664-2295</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fneur.2026.1746101</article-id>
<article-version article-version-type="Version of Record" vocab="NISO-RP-8-2008"/>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Research</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The effect of levodopa on speech graphs in non-demented patients with multiple system atrophy and Parkinson&#x2019;s disease</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Liu</surname>
<given-names>Jingyue</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="author-notes" rid="fn0001"><sup>&#x2020;</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/1716080"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x0026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &#x0026; editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Zhao</surname>
<given-names>Yan</given-names>
</name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="author-notes" rid="fn0001"><sup>&#x2020;</sup></xref>
<role>reviewer</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x0026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &#x0026; editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ma</surname>
<given-names>Jinghong</given-names>
</name>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/1228699"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x0026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &#x0026; editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Zhang</surname>
<given-names>Guanyu</given-names>
</name>
<xref ref-type="aff" rid="aff4"><sup>4</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>&#x002A;</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/680043"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
</contrib>
</contrib-group>
<aff id="aff1"><label>1</label><institution>National Clinical Research Center for Geriatric Disorders, Xuanwu Hospital of Capital Medical University</institution>, <city>Beijing</city>, <country country="cn">China</country></aff>
<aff id="aff2"><label>2</label><institution>Department of Rehabilitation Medicine, Jinan Third People&#x2019;s Hospital</institution>, <city>Jinan</city>, <country country="cn">China</country></aff>
<aff id="aff3"><label>3</label><institution>Department of Neurology, Xuanwu Hospital of Capital Medical University</institution>, <city>Beijing</city>, <country country="cn">China</country></aff>
<aff id="aff4"><label>4</label><institution>China Institute of Sport Science</institution>, <city>Beijing</city>, <country country="cn">China</country></aff>
<author-notes>
<corresp id="c001"><label>&#x002A;</label>Correspondence: Guanyu Zhang, <email xlink:href="mailto:1601466858@qq.com">1601466858@qq.com</email></corresp>
<fn fn-type="equal" id="fn0001">
<label>&#x2020;</label>
<p>These authors share first authorship</p>
</fn>
</author-notes>
<pub-date publication-format="electronic" date-type="pub" iso-8601-date="2026-02-09">
<day>09</day>
<month>02</month>
<year>2026</year>
</pub-date>
<pub-date publication-format="electronic" date-type="collection">
<year>2026</year>
</pub-date>
<volume>17</volume>
<elocation-id>1746101</elocation-id>
<history>
<date date-type="received">
<day>14</day>
<month>11</month>
<year>2025</year>
</date>
<date date-type="rev-recd">
<day>22</day>
<month>01</month>
<year>2026</year>
</date>
<date date-type="accepted">
<day>26</day>
<month>01</month>
<year>2026</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x00A9; 2026 Liu, Zhao, Ma and Zhang.</copyright-statement>
<copyright-year>2026</copyright-year>
<copyright-holder>Liu, Zhao, Ma and Zhang</copyright-holder>
<license>
<ali:license_ref start_date="2026-02-09">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License (CC BY)</ext-link>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<sec>
<title>Background</title>
<p>An objective topological analysis for any arbitrary network was provided by graph theory, which was implemented to reveal topological properties of brain networks in a wide range of neurodegenerative diseases.</p>
</sec>
<sec>
<title>Objectives</title>
<p>To investigate the difference of the topology of speech graphs among parkinsonian-type multiple system atrophy patients (MSA-P), idiopathic Parkinson&#x2019;s disease (PD) patients, and healthy controls (HC). To explore the effect of levodopa on the topology of speech graphs in MSA-P and PD patients.</p>
</sec>
<sec>
<title>Methods</title>
<p>We applied a graph analysis of topology of speech graphs in MSA-P patients (<italic>N</italic>&#x202F;=&#x202F;39), idiopathic PD patients (<italic>N</italic>&#x202F;=&#x202F;51), and HC (<italic>N</italic>&#x202F;=&#x202F;51). All participants were assessed by a well-established semantic fluency test (animal). Participants&#x2019; verbal reactions were listed and represented as speech graphs with directionality.</p>
</sec>
<sec>
<title>Results</title>
<p>MSA-P patients mentioned more about their memory and remaining time than PD patients (<italic>p</italic>&#x202F;&#x003C;&#x202F;0.001) and HC (<italic>p</italic>&#x202F;&#x003C;&#x202F;0.001). Moreover, MSA-P patients&#x2019; speech graphs exhibited fewer nodes (PD: <italic>p</italic>&#x202F;=&#x202F;0.004; HC: <italic>p</italic>&#x202F;&#x003C;&#x202F;0.001), higher density (PD: <italic>p</italic>&#x202F;=&#x202F;0.007; HC: <italic>p</italic>&#x202F;&#x003C;&#x202F;0.001), smaller diameter (PD: <italic>p</italic>&#x202F;=&#x202F;0.004; HC: <italic>p</italic>&#x202F;&#x003C;&#x202F;0.001), and smaller average shortest path (PD: <italic>p</italic>&#x202F;=&#x202F;0.002; HC: <italic>p</italic>&#x202F;&#x003C;&#x202F;0.001) than both PD patients and HC. Compared with PD patients and healthy adults, the MSA-P patients generated denser and smaller speech graphs. Importantly, in MSA-P, the positive correlations between levodopa equivalent daily dose and diameter (<italic>r</italic>&#x202F;=&#x202F;0.39, <italic>p</italic>&#x202F;=&#x202F;0.017) and average shortest path (<italic>r</italic>&#x202F;=&#x202F;0.38, <italic>p</italic>&#x202F;=&#x202F;0.017) were obtained, suggesting that higher levodopa doses were associated with producing sparser and larger speech graphs in MSA-P patients. However, there was no significant correlation between levodopa equivalent daily dose and graph indices in PD patients.</p>
</sec>
<sec>
<title>Conclusion</title>
<p>MSA-P patients&#x2019; speech graphs were denser and smaller than both PD patients and healthy adults. The graph analysis of semantic fluency can differentiate MSA-P from PD to some extent. Importantly, in MSA-P patients, the impaired speech topology can be partially restored by levodopa.</p>
</sec>
</abstract>
<kwd-group>
<kwd>cognition</kwd>
<kwd>levodopa equivalent daily dose</kwd>
<kwd>multiple system atrophy</kwd>
<kwd>semantic fluency</kwd>
<kwd>speech graphs</kwd>
</kwd-group>
<funding-group>
<funding-statement>The author(s) declared that financial support was received for this work and/or its publication. This study was supported by the Fundamental Research Funds for the China Institute of Sport Science (24&#x2013;48 to GZ).</funding-statement>
</funding-group>
<counts>
<fig-count count="3"/>
<table-count count="1"/>
<equation-count count="0"/>
<ref-count count="31"/>
<page-count count="7"/>
<word-count count="4579"/>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Cognitive and Behavioral Neurology</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec sec-type="intro" id="sec1">
<label>1</label>
<title>Introduction</title>
<p>Multiple system atrophy (MSA) is defined by striatonigral and olivopontocerebellar degenerations with various combinations of autonomic, extrapyramidal, and cerebellar symptoms (<xref ref-type="bibr" rid="ref1">1</xref>). MSA has many clinical phenotypes, such as parkinsonian-type MSA (MSA-P) and cerebellar-type MSA (MSA-C). Usually, it has difficulties in differentiating between early-stage MSA-P and idiopathic Parkinson&#x2019;s disease (PD), because they share similar clinical features (<xref ref-type="bibr" rid="ref2">2</xref>). Therefore, a effective tool to differentiate MSA-P from idiopathic PD is clinically meaningful.</p>
<p>The well-established semantic fluency test has been frequently used measure in research and clinical practice for assessing the ability to produce as many different words of a specific category (e.g., animal) as possible during one minute (<xref ref-type="bibr" rid="ref3">3</xref>). Many parameters have been proposed for measuring the performance of this test, for example, the count of correct words of MSA or PD patients was lower than healthy adults (<xref ref-type="bibr" rid="ref4">4</xref>, <xref ref-type="bibr" rid="ref5">5</xref>). Clustering and switching analyses are also common, which defined two key parameters based on the similarity or closeness of word meaning (<xref ref-type="bibr" rid="ref6">6</xref>). The average count of correct words with high semantic relatedness (e.g., invertebrate animals) is defined as the mean cluster size, and the count of cluster switches. Compared to healthy adults, the PD, Alzheimer&#x2019;s disease (AD), or progressive supranuclear palsy (PSP) patients exhibited fewer clusters and switches in verbal fluency tests (<xref ref-type="bibr" rid="ref7">7</xref>, <xref ref-type="bibr" rid="ref8">8</xref>). However, this approach obtains limited information and depends primarily upon subjective estimation of cluster division. An automated classification approach conflicted with classic experimenter-based method in evaluating clusters (<xref ref-type="bibr" rid="ref9">9</xref>).</p>
<p>An objective approach originates from graph theory, which calculates network properties to provide an assessment of network structure and changes. The graph theoretical analyses have been implemented to depict the topological dynamics of brain networks in a variety of neurodegenerative disorders (<xref ref-type="bibr" rid="ref10">10</xref>, <xref ref-type="bibr" rid="ref11">11</xref>). Similarly, this approach have been used to analyze semantic fluency data. Our previous studies found that AD patients&#x2019; speech graphs exhibited fewer nodes, higher density, smaller diameter, and smaller average shortest path than PD patients (<xref ref-type="bibr" rid="ref12">12</xref>), which was same as the comparison between PSP patients and PD patients (<xref ref-type="bibr" rid="ref13">13</xref>), suggesting that the cognitive decline associated with denser and smaller speech graphs.</p>
<p>This study used graph theoretical analysis to investigate the speech topology of MSA-P patients. All participants were assessed by a well-established semantic fluency test (animal). Their verbal reactions were listed and represented as speech graphs with directionality. A node represents a correct word and an arc represents the temporal connection between sequential words. First, group differences in meta references (metalinguistic reference and metacognitive reference) and graph indices (nodes, density, diameter, and average shortest path) were examined. Second, the effects of levodopa on meta references or graph indices were explored in MSA-P and PD, respectively.</p>
</sec>
<sec sec-type="materials|methods" id="sec2">
<label>2</label>
<title>Materials and methods</title>
<sec id="sec3">
<label>2.1</label>
<title>Patients and clinical assessments</title>
<p>We included 39 patients with MSA-P (Movement Disorder Society Clinical Diagnostic Criteria for Multiple System Atrophy (<xref ref-type="bibr" rid="ref14">14</xref>)) at the Xuanwu Hospital of Capital Medical University between 2024&#x2013;2025.</p>
<p>All patients were evaluated on their regular anti-parkinsonian drugs, including levodopa (<italic>N</italic>&#x202F;=&#x202F;31), amantadine (<italic>N</italic>&#x202F;=&#x202F;17), pramipexole (<italic>N</italic>&#x202F;=&#x202F;11), stalevo (<italic>N</italic>&#x202F;=&#x202F;9), selegiline (<italic>N</italic>&#x202F;=&#x202F;4), rasagiline (<italic>N</italic>&#x202F;=&#x202F;2), and benzhexol (<italic>N</italic>&#x202F;=&#x202F;1). Anti-parkinsonian drugs were calculated according to the formula of Tomlinson et al. (<xref ref-type="bibr" rid="ref15">15</xref>) that yielded a total levodopa equivalent daily dose. The Movement Disorder Society sponsored revision of the Unified Parkinson&#x2019;s disease Rating Scale (MDS-UPDRS) was expanded upon the original UPDRS by including more non-motor items, making it become a robust tool to evaluate the severity of motor (Part III subscale) and non-motor symptoms (Part I subscale). Demographic and clinical assessments and neuropsychological features were demonstrated in <xref ref-type="table" rid="tab1">Table 1</xref>. For comparison between the MSA and PD groups, there was no difference in the MoCA (<italic>p</italic>&#x202F;=&#x202F;0.294), even though the difference among three groups was significant.</p>
<table-wrap position="float" id="tab1">
<label>Table 1</label>
<caption>
<p>Demographic and clinical assessments, and neuropsychological features of patients and healthy controls (means, standard deviations, ranges, and group differences).</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="top">Assessments/features</th>
<th align="center" valign="top">MSA-P<break/>(<italic>N</italic> =&#x202F;39)</th>
<th align="center" valign="top">PD<break/>(<italic>N</italic> =&#x202F;51)</th>
<th align="center" valign="top">HC<break/>(<italic>N</italic> =&#x202F;51)</th>
<th align="center" valign="top">Group differences (<italic>p</italic> values)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="middle">Male: female</td>
<td align="center" valign="middle">18:21</td>
<td align="center" valign="middle">26:25</td>
<td align="center" valign="middle">24:27</td>
<td align="center" valign="middle">0.883</td>
</tr>
<tr>
<td align="left" valign="middle">Age (years)</td>
<td align="center" valign="middle">61.2 (7.8)<break/>45&#x2013;79</td>
<td align="center" valign="middle">59.2 (10.1)<break/>41&#x2013;80</td>
<td align="center" valign="middle">59.0 (7.6)<break/>40&#x2013;74</td>
<td align="center" valign="middle">0.439</td>
</tr>
<tr>
<td align="left" valign="middle">Education (years)</td>
<td align="center" valign="middle">11.4 (3.3)<break/>5&#x2013;19</td>
<td align="center" valign="middle">12.3 (3.2)<break/>6&#x2013;18</td>
<td align="center" valign="middle">11.9 (2.2)<break/>7&#x2013;16</td>
<td align="center" valign="middle">0.373</td>
</tr>
<tr>
<td align="left" valign="middle" colspan="5">Motor symptoms</td>
</tr>
<tr>
<td align="left" valign="middle">MDS-UPDRS III: motor examination</td>
<td align="center" valign="middle">36.9 (14.1)<break/>4&#x2013;66</td>
<td align="center" valign="middle">32.6 (11.4)<break/>12&#x2013;55</td>
<td align="center" valign="middle">&#x2014;</td>
<td align="center" valign="middle">0.117</td>
</tr>
<tr>
<td align="left" valign="middle">Hoehn and Yahr scale</td>
<td align="center" valign="middle">2.3 (0.7)<break/>1&#x2013;3</td>
<td align="center" valign="middle">2.1 (0.6)<break/>1&#x2013;3</td>
<td align="center" valign="middle">&#x2014;</td>
<td align="center" valign="middle">0.103</td>
</tr>
<tr>
<td align="left" valign="middle">Disease duration (years)</td>
<td align="center" valign="middle">0.9 (1.2)<break/>0&#x2013;5</td>
<td align="center" valign="middle">1.3 (1.5)<break/>0&#x2013;5</td>
<td align="center" valign="middle">&#x2014;</td>
<td align="center" valign="middle">0.124</td>
</tr>
<tr>
<td align="left" valign="middle">Duration of motor symptoms (years)</td>
<td align="center" valign="middle">2.4 (1.2)<break/>1&#x2013;6</td>
<td align="center" valign="middle">2.6 (2.0)<break/>0&#x2013;9</td>
<td align="center" valign="middle">&#x2014;</td>
<td align="center" valign="middle">0.535</td>
</tr>
<tr>
<td align="left" valign="middle">Levodopa equivalent daily dose (mg/day)</td>
<td align="center" valign="middle">388.2 (224.5)<break/>25&#x2013;875</td>
<td align="center" valign="middle">313.2 (229.4)<break/>38&#x2013;1,000</td>
<td align="center" valign="middle">&#x2014;</td>
<td align="center" valign="middle">0.124</td>
</tr>
<tr>
<td align="left" valign="middle" colspan="5">Non-motor functions</td>
</tr>
<tr>
<td align="left" valign="middle">MDS-UPDRS I: non-motor experiences of daily living</td>
<td align="center" valign="middle">11.4 (5.6)<break/>2&#x2013;24</td>
<td align="center" valign="middle">9.9 (4.6)<break/>3&#x2013;21</td>
<td align="center" valign="middle">&#x2014;</td>
<td align="center" valign="middle">0.166</td>
</tr>
<tr>
<td align="left" valign="middle">Beck depression inventory-II</td>
<td align="center" valign="middle">4.2 (2.8)<break/>0&#x2013;7</td>
<td align="center" valign="middle">3.3 (2.0)<break/>0&#x2013;7</td>
<td align="center" valign="middle">3.3 (1.7)<break/>0&#x2013;7</td>
<td align="center" valign="middle">0.105</td>
</tr>
<tr>
<td align="left" valign="middle">Epworth sleep scale</td>
<td align="center" valign="middle">4.1 (2.7)<break/>0&#x2013;10</td>
<td align="center" valign="middle">3.9 (3.7)<break/>0&#x2013;14</td>
<td align="center" valign="middle">3.4 (2.5)<break/>0&#x2013;10</td>
<td align="center" valign="middle">0.536</td>
</tr>
<tr>
<td align="left" valign="middle">Montreal cognitive assessment</td>
<td align="center" valign="middle">24.9 (2.4)<break/>21&#x2013;30</td>
<td align="center" valign="middle">25.4 (2.6)<break/>21&#x2013;30</td>
<td align="center" valign="middle">27.9 (1.4)<break/>26&#x2013;30</td>
<td align="center" valign="middle">&#x003C;0.001&#x002A;</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p>MSA-P, parkinsonian-type multiple system atrophy; PD, Parkinson&#x2019;s disease; HC, healthy controls; MDS-UPDRS, the Movement Disorder Society-sponsored revision of the Unified Parkinson&#x2019;s disease rating scale; Group differences, <italic>p</italic> values of one-way ANOVAs or Kruskal-Wallis one-way ANOVAs as appropriate; asterisks (&#x002A;), a significant group difference.</p>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec4">
<label>2.2</label>
<title>Two control groups</title>
<p>This study recruited two control groups: 51 age, sex, and education-matched idiopathic PD patients [Movement Disorder Society Clinical Diagnostic Criteria for Parkinson&#x2019;s disease (<xref ref-type="bibr" rid="ref16">16</xref>)] from Xuanwu Hospital of Capital Medical University and 51 age, sex, and education-matched healthy controls (HC) from nearby communities.</p>
<p>For the PD group, they were evaluated on their regular anti-parkinsonian drugs, including levodopa (<italic>N</italic>&#x202F;=&#x202F;37), pramipexole (<italic>N</italic>&#x202F;=&#x202F;17), selegiline (<italic>N</italic>&#x202F;=&#x202F;11), piribedil (<italic>N</italic>&#x202F;=&#x202F;10), amantadine (<italic>N</italic>&#x202F;=&#x202F;5), and entacapone (<italic>N</italic>&#x202F;=&#x202F;3). As MSA-P patients, they completed the same neuropsychological and clinical measures.</p>
<p>For the HC group, they completed the same measures for mood, sleep, and cognition as patients.</p>
</sec>
<sec id="sec5">
<label>2.3</label>
<title>The inclusion and exclusion criteria</title>
<p>For all groups, inclusion criteria were (1) age 40 to 80&#x202F;years; (2) education &#x2265;5&#x202F;years; (3) Mandarin Chinese speaking (native or fluent Mandarin Chinese speakers). Exclusion criteria were (1) intake of anti-depressants or potential current depression (Beck Depression Inventory-II, BDI-II&#x202F;&#x003E;&#x202F;7); (2) a history of brain injury or neurological or psychiatric disorders or inherited diseases; (3) drug or alcohol abuse.</p>
<p>For MSA-P and PD groups, inclusion criteria added Hoehn and Yahr Stages 1 to 3 and exclusion criteria added intake of anti-dementia drugs or potential current dementia (Montreal Cognitive Assessment, MoCA&#x003C;21/30). Particularly, there was no MSA-P patient who did not receive levodopa (levodopa equivalent daily dose&#x202F;=&#x202F;0&#x202F;mg/day).</p>
<p>For HC group, exclusion criteria added intake of anti-dementia drugs or potential current mild cognitive impairment or dementia (MoCA&#x003C;26/30).</p>
</sec>
<sec id="sec6">
<label>2.4</label>
<title>Meta references and graph indices</title>
<p>All participants were assessed by a well-established semantic fluency test (animal). Their verbal reactions were listed.</p>
<p>The two meta references were: (1) metalinguistic reference: the count of times participants mentioned about words they generated (e.g., &#x201C;Is it right to say shrimp?&#x201D;); (2) metacognitive reference: the count of times participants mentioned about their ability to complete this task or asked remaining time (e.g., &#x201C;I can&#x2019;t do this.&#x201D;).</p>
<p>Participants&#x2019; verbal reactions were represented as speech graphs with directionality by Speech graph software (<xref ref-type="bibr" rid="ref12">12</xref>, <xref ref-type="bibr" rid="ref13">13</xref>), in which a node represents a correct word and an arc represents the temporal connection between sequential words (<xref ref-type="fig" rid="fig1">Figure 1</xref>). We calculated four graph indices, including the nodes, density, diameter, and average shortest path. The correct words are the nodes. The ratio of the count of arcs to the maximum possible count of arcs is the density. The length of the longest shortest path between two nodes is the diameter. The mean length of all the shortest paths between two nodes is the average shortest path.</p>
<fig position="float" id="fig1">
<label>Figure 1</label>
<caption>
<p>Diagram of speech graphs with directionality of three typical participants: MSA038, a parkinsonian-type multiple system atrophy patient; PD068, a idiopathic Parkinson&#x2019;s disease patient; HC032, a healthy control subject. Examples of the shortest path (green) between two nodes (blue) in the three speech graphs with directionality. The nodes represent correct words. The arcs represent temporal connection between nodes. The density is the ratio of the count of arcs to the maximum possible count of arcs. The diameter is the length of the longest shortest path. The average shortest path is the mean length of all the shortest paths. It can be clearly seen from the figure that the speech graphs of three participants from three different groups became sparser and larger in sequence.</p>
</caption>
<graphic xlink:href="fneur-17-1746101-g001.tif" mimetype="image" mime-subtype="tiff">
<alt-text content-type="machine-generated">Three labeled directed network diagrams represent animal name associations for MSA038, PD068, and HC032. Each network has animal names in red or blue circles, connected by black and green arrows showing relationships, forming distinct patterns for each individual.</alt-text>
</graphic>
</fig>
</sec>
<sec id="sec7">
<label>2.5</label>
<title>Statistical analysis</title>
<p>The statistical data analysis was performed with IBM SPSS Statistics Version 20. First, one-way ANOVAs were used for exploring group differences in the meta references and graph indices (two-tailed, <italic>p</italic>&#x202F;&#x003C;&#x202F;0.05). The ANOVA had a factor Group (MSA-P, PD, and HC). <italic>Post hoc</italic> tests were used after observing significant group differences.</p>
<p>Second, partial correlation analyses were used for exploring the relationship between levodopa equivalent daily dose and the meta references and graph indices that exhibited group differences in MSA-P and PD groups, respectively (two-tailed, <italic>p</italic>&#x202F;&#x003C;&#x202F;0.05). The MDS-UPDRS Part III score was controlled. There was no covariate.</p>
</sec>
</sec>
<sec sec-type="results" id="sec8">
<label>3</label>
<title>Results</title>
<sec id="sec9">
<label>3.1</label>
<title>Group differences in meta references</title>
<p><xref ref-type="fig" rid="fig2">Figure 2A</xref> shows meta references in each group. Group difference was obtained in the metacognitive reference [<italic>F</italic>(2, 138)&#x202F;=&#x202F;30.70, <italic>p&#x202F;&#x003C;</italic> 0.001, &#x03B7;<italic><sub>p</sub></italic><sup>2</sup>&#x202F;=&#x202F;0.31], but not in the metalinguistic reference [<italic>F</italic>(2, 138)&#x202F;=&#x202F;1.97, <italic>p&#x202F;=</italic> 0.144, &#x03B7;<italic><sub>p</sub></italic><sup>2</sup>&#x202F;=&#x202F;0.03]. Compared to PD patients and HC, the MSA-P patients mentioned more about their memory and remaining time (PD: <italic>p&#x202F;&#x003C;</italic> 0.001; HC: <italic>p&#x202F;&#x003C;</italic> 0.001).</p>
<fig position="float" id="fig2">
<label>Figure 2</label>
<caption>
<p><bold>(A)</bold> Means and standard errors of metalinguistic and metacognitive references in parkinsonian-type multiple system atrophy patients (MSA-P), idiopathic Parkinson&#x2019;s disease patients (PD), and healthy controls (HC). <bold>(B)</bold> Means and standard errors of nodes, density, diameter, and average shortest path in three groups. Asterisks (&#x002A;) mean significant group differences between MSA-P and PD or HC in meta references and graph indices.</p>
</caption>
<graphic xlink:href="fneur-17-1746101-g002.tif" mimetype="image" mime-subtype="tiff">
<alt-text content-type="machine-generated">Figure shows dot and violin plots comparing measures across MSA-P, PD, and HC groups. Plots in section A display metalinguistics and metacognition times. Section B contains plots for nodes, density, diameter, and average shortest path, indicating significant group differences with asterisks.</alt-text>
</graphic>
</fig>
</sec>
<sec id="sec10">
<label>3.2</label>
<title>Group differences in graph indices</title>
<p><xref ref-type="fig" rid="fig2">Figure 2B</xref> shows graph indices in each group. Group differences were obtained in the nodes [<italic>F</italic>(2, 138)&#x202F;=&#x202F;9.77, <italic>p&#x202F;&#x003C;</italic> 0.001, &#x03B7;<italic>
<sub>p</sub>
</italic><sup>2</sup>&#x202F;=&#x202F;0.12], density [<italic>F</italic>(2, 138)&#x202F;=&#x202F;9.10, <italic>p&#x202F;&#x003C;</italic> 0.001, &#x03B7;<italic>
<sub>p</sub>
</italic><sup>2</sup>&#x202F;=&#x202F;0.12], diameter [<italic>F</italic>(2, 138)&#x202F;=&#x202F;8.82, <italic>p&#x202F;&#x003C;</italic> 0.001, &#x03B7;<italic>
<sub>p</sub>
</italic><sup>2</sup>&#x202F;=&#x202F;0.11], and average shortest path [<italic>F</italic>(2, 138)&#x202F;=&#x202F;10.08, <italic>p&#x202F;&#x003C;</italic> 0.001, &#x03B7;<italic>
<sub>p</sub>
</italic><sup>2</sup>&#x202F;=&#x202F;0.13]. Compared to PD patients and HC, the MSA-P group showed fewer nodes (PD: <italic>p</italic>&#x202F;=&#x202F;0.004; HC: <italic>p&#x202F;&#x003C;</italic> 0.001), higher density (PD: <italic>p</italic>&#x202F;=&#x202F;0.007; HC: <italic>p&#x202F;&#x003C;</italic> 0.001), smaller diameter (PD: <italic>p</italic>&#x202F;=&#x202F;0.004; HC: <italic>p&#x202F;&#x003C;</italic> 0.001), and smaller average shortest path (PD: <italic>p</italic>&#x202F;=&#x202F;0.002; HC: <italic>p&#x202F;&#x003C;</italic> 0.001). Specifically, MSA-P patients&#x2019; speech graphs were denser and smaller than PD patients and HC.</p>
</sec>
<sec id="sec11">
<label>3.3</label>
<title>Effect of levodopa in MSA-P and PD patients</title>
<p><xref ref-type="fig" rid="fig3">Figure 3</xref> shows the effect of levodopa on graph indices in MSA-P and PD patients, respectively. For the MSA-P patients, when the MDS-UPDRS Part III score was controlled, the positive correlations between levodopa equivalent daily dose and the diameter (<italic>r</italic>&#x202F;=&#x202F;0.39, <italic>p</italic>&#x202F;=&#x202F;0.017) and average shortest path (<italic>r</italic>&#x202F;=&#x202F;0.38, <italic>p</italic>&#x202F;=&#x202F;0.017) were obtained. It suggested that higher levodopa doses were associated with producing sparser and larger speech graphs in MSA-P patients. For the PD patients, we did not acquire the significant correlation between levodopa equivalent daily dose and diameter or average shortest path (<italic>p</italic>s&#x003E;0.870).</p>
<fig position="float" id="fig3">
<label>Figure 3</label>
<caption>
<p>In MSA-P, the positive correlations between levodopa equivalent daily dose and diameter and average shortest path when the MDS-UPDRS part III score was controlled. In PD, there was no significant correlation. Values were demeaned.</p>
</caption>
<graphic xlink:href="fneur-17-1746101-g003.tif" mimetype="image" mime-subtype="tiff">
<alt-text content-type="machine-generated">Four scatter plots compare metrics in MSA-P and PD patients. Top row shows diameter versus levodopa equivalent daily dose; MSA-P has a positive correlation (r equals 0.39, p equals 0.017) while PD shows no correlation (r equals negative 0.02, p equals 0.915). Bottom row shows average shortest path versus levodopa equivalent daily dose; MSA-P again has a positive correlation (r equals 0.38, p equals 0.017) while PD has none (r equals negative 0.02, p equals 0.870). Axes are labeled in arbitrary units.</alt-text>
</graphic>
</fig>
<p>There was no significant correlation between levodopa equivalent daily dose and other indices (<italic>p</italic>s&#x003E;0.291).</p>
</sec>
</sec>
<sec sec-type="discussion" id="sec12">
<label>4</label>
<title>Discussion</title>
<p>This study applied the graph theoretical analysis for investigating the topology of speech graphs in non-demented patients with MSA-P. Compared to PD patients and healthy adults, MSA-P patients produced denser and smaller speech graphs. Specifically, MSA-P patients&#x2019; speech graphs exhibited fewer nodes, higher density, smaller diameter, and smaller average shortest path in comparison to both PD patients and healthy adults. This study confirmed that graph theoretical analyses could differentiate MSA-P and PD, which is similar to a previous study. &#x0160;ubert et al. (<xref ref-type="bibr" rid="ref17">17</xref>) used the automated linguistic analysis of natural spontaneous speech and also achieved this goal. Importantly, in MSA-P patients, the positive correlations between levodopa equivalent daily dose and diameter and average shortest path were obtained. Particularly, there was no MSA-P patient who did not receive levodopa (levodopa equivalent daily dose&#x202F;=&#x202F;0&#x202F;mg/day). It suggested that higher levodopa doses were associated with producing sparser and larger speech graphs in MSA-P patients.</p>
<p>Additionally, the increased meta-references may be because of deficits in both lexical retrieval and executive control. Prefrontal cortex has long been considered essential for option generation (nodes) and executive functions. A fMRI study showed that the prefrontal cortex activation was related to option production in simple real-world scenarios (<xref ref-type="bibr" rid="ref18">18</xref>). Enhanced left prefrontal activation has been observed in the word generation within a semantically similar category (<xref ref-type="bibr" rid="ref19">19</xref>). Moreover, the left inferior frontal gyrus modulate the verbal responses production that satisfy the instruction and inhibit irrelevant words (<xref ref-type="bibr" rid="ref20">20</xref>). It has been confirmed that executive control is realized by the prefrontal cortex that sends command signals to supervise and control the activities in other cortical and subcortical regions (<xref ref-type="bibr" rid="ref21">21</xref>).</p>
<p>In addition, the basal ganglia also participated in speech initiation and programming. An electrophysiological research used microelectrode recordings and found that sensori-motor subthalamic neuronal activity was associated with generating speech programming during spoken sentence and syllable-repetition tasks (<xref ref-type="bibr" rid="ref22">22</xref>). A MRI study investigated the contribution of basal ganglia on verbal fluency and exhibited that the caudate nucleus associated with language generation and the putamen activation improved the switching condition (<xref ref-type="bibr" rid="ref23">23</xref>).</p>
<p>The speech topological abnormalities in MSA-P patients may result from aberrant connectivity of the frontal-basal ganglionic circuits compared to PD patients (<xref ref-type="bibr" rid="ref24">24</xref>). A PET study confirmed that the frontal, temporal, parietal, and limbic hypometabolism was associated with cognitive decline in MSA patients (<xref ref-type="bibr" rid="ref25">25</xref>). Another thin section MR study pointed out that the putaminal signal abnormalities and hyperintensities on proton density were more common in MSA-P patients compared to PD patients (<xref ref-type="bibr" rid="ref26">26</xref>).</p>
<p>Neurochemical basis of speech graph is still unclear. A model suggested that the dopamine modulating fronto-striatal circuitry might relevant to the persistence and flexibility, respectively (<xref ref-type="bibr" rid="ref27">27</xref>). To be specific, appropriate dopamine levels in prefrontal cortex promote persistent processes (words generation within a specific category or subcategory) along the mesocortical pathway, while appropriate dopamine levels in striatum accelerate flexible processes (words generation within different categories or subcategories) along the nigrostriatal pathway. Dual-state theory indicated that the prefrontal cortex with concentrated dopamine D1 receptor supports maintenance of item, while the striatum with concentrated dopamine D2 receptor favors flexibility of item (<xref ref-type="bibr" rid="ref28">28</xref>). A previous study proposed that the levodopa, rather than dopamine agonist pramipexole, could enhance verbal fluency in PD patients (<xref ref-type="bibr" rid="ref29">29</xref>). There also have conflicting results. For example, Subert et al. (<xref ref-type="bibr" rid="ref30">30</xref>) found that PD patients who were treated with dopamine agonists showed improvement in sentence length, while who were treated with levodopa had no language amelioration. This study showed that levodopa could improve speech graphs in MSA-P patients. These results may be possibly by activating dopamine D1 receptors (<xref ref-type="bibr" rid="ref31">31</xref>).</p>
<p>This study has limitations. First, in view of the small sample size of MSA patients with other clinical phenotypes and increasing global homogeneity, we only include patients with MSA-P, thus it&#x2019;s impossible for this study to differentiate between MSA-P and other clinical phenotypes by graph theory-based analysis of semantic fluency data. Second, although we found the relationship between levodopa equivalent daily dose and graph indices, it cannot be regarded as a causal conclusion. Third, there were very few MSA-P patients took dopamine D2 receptor agonists, thus this study cannot examine the effect of activating dopamine D2 receptor on speech graphs. Future pharmacological researches should explore how antiparkinsonian medications affect speech topology in MSA patients.</p>
</sec>
<sec sec-type="conclusions" id="sec13">
<label>5</label>
<title>Conclusion</title>
<p>This study applied graph theory to demonstrate the topological properties of speech graphs in MSA-P patients, indicating that MSA-P patients&#x2019; speech graphs were denser and smaller in comparison to PD patients and healthy adults. Moreover, higher levodopa doses were associated with producing sparser and larger speech graphs in MSA-P patients, indicating that the impaired speech topology can be partially restored by levodopa. Future studies should explore long-term successful treatments to achieve the improvement of speech topology in MSA-P patients.</p>
</sec>
</body>
<back>
<sec sec-type="data-availability" id="sec14">
<title>Data availability statement</title>
<p>The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.</p>
</sec>
<sec sec-type="ethics-statement" id="sec15">
<title>Ethics statement</title>
<p>The studies involving humans were approved by the ethics committee of the Xuanwu Hospital. The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent for participation in this study was provided by the participants&#x2019; legal guardians/next of kin.</p>
</sec>
<sec sec-type="author-contributions" id="sec16">
<title>Author contributions</title>
<p>JL: Writing &#x2013; review &#x0026; editing, Data curation, Validation. YZ: Writing &#x2013; review &#x0026; editing, Data curation, Validation. JM: Data curation, Writing &#x2013; review &#x0026; editing, Validation. GZ: Writing &#x2013; original draft, Funding acquisition, Formal analysis, Visualization, Data curation.</p>
</sec>
<ack>
<title>Acknowledgments</title>
<p>We are thankful to Yinuo Zhang, Shaoyang Ma, and Minghong Su for their participation in data collection.</p>
</ack>
<sec sec-type="COI-statement" id="sec17">
<title>Conflict of interest</title>
<p>The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="ai-statement" id="sec18">
<title>Generative AI statement</title>
<p>The author(s) declared that Generative AI was not used in the creation of this manuscript.</p>
<p>Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.</p>
</sec>
<sec sec-type="disclaimer" id="sec19">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="ref1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fanciulli</surname><given-names>A</given-names></name> <name><surname>Wenning</surname><given-names>GK</given-names></name></person-group>. <article-title>Multiple-system atrophy</article-title>. <source>N Engl J Med</source>. (<year>2015</year>) <volume>372</volume>:<fpage>249</fpage>&#x2013;<lpage>63</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJMra1311488</pub-id></mixed-citation></ref>
<ref id="ref2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamamoto</surname><given-names>T</given-names></name> <name><surname>Sakakibara</surname><given-names>R</given-names></name> <name><surname>Uchiyama</surname><given-names>T</given-names></name> <name><surname>Yamaguchi</surname><given-names>C</given-names></name> <name><surname>Nomura</surname><given-names>F</given-names></name> <name><surname>Ito</surname><given-names>T</given-names></name> <etal/></person-group>. <article-title>Pelvic organ dysfunction is more prevalent and severe in MSA-P compared to Parkinson&#x2019;s disease</article-title>. <source>Neurourol Urodyn</source>. (<year>2011</year>) <volume>30</volume>:<fpage>102</fpage>&#x2013;<lpage>7</lpage>. doi: <pub-id pub-id-type="doi">10.1002/nau.20948</pub-id>, <pub-id pub-id-type="pmid">20658542</pub-id></mixed-citation></ref>
<ref id="ref3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ardila</surname><given-names>A</given-names></name> <name><surname>Ostrosky-Sol&#x00ED;s</surname><given-names>F</given-names></name> <name><surname>Bernal</surname><given-names>B</given-names></name></person-group>. <article-title>Cognitive testing toward the future: the example of semantic verbal fluency (ANIMALS)</article-title>. <source>Int J Psychol</source>. (<year>2006</year>) <volume>41</volume>:<fpage>324</fpage>&#x2013;<lpage>32</lpage>. doi: <pub-id pub-id-type="doi">10.1080/00207590500345542</pub-id></mixed-citation></ref>
<ref id="ref4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawai</surname><given-names>Y</given-names></name> <name><surname>Suenaga</surname><given-names>M</given-names></name> <name><surname>Takeda</surname><given-names>A</given-names></name> <name><surname>Ito</surname><given-names>M</given-names></name> <name><surname>Watanabe</surname><given-names>H</given-names></name> <name><surname>Tanaka</surname><given-names>F</given-names></name> <etal/></person-group>. <article-title>Cognitive impairments in multiple system atrophy: MSA-C <italic>vs.</italic> MSA-P</article-title>. <source>Neurology</source>. (<year>2008</year>) <volume>70</volume>:<fpage>1390</fpage>&#x2013;<lpage>6</lpage>. doi: <pub-id pub-id-type="doi">10.1212/01.wnl.0000310413.04462.6a</pub-id>, <pub-id pub-id-type="pmid">18413566</pub-id></mixed-citation></ref>
<ref id="ref5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>J</given-names></name> <name><surname>McMahon</surname><given-names>KL</given-names></name> <name><surname>Copland</surname><given-names>DA</given-names></name> <name><surname>Pourzinal</surname><given-names>D</given-names></name> <name><surname>Byrne</surname><given-names>GJ</given-names></name> <name><surname>Angwin</surname><given-names>AJ</given-names></name> <etal/></person-group>. <article-title>Semantic fluency deficits and associated brain activity in Parkinson&#x2019;s disease with mild cognitive impairment</article-title>. <source>Brain Imaging Behav</source>. (<year>2022</year>) <volume>16</volume>:<fpage>2445</fpage>&#x2013;<lpage>56</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s11682-022-00698-7</pub-id>, <pub-id pub-id-type="pmid">35841523</pub-id></mixed-citation></ref>
<ref id="ref6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Troyer</surname><given-names>AK</given-names></name> <name><surname>Moscovitch</surname><given-names>M</given-names></name> <name><surname>Winocur</surname><given-names>G</given-names></name></person-group>. <article-title>Clustering and switching as two components of verbal fluency: evidence from younger and older healthy adults</article-title>. <source>Neuropsychology</source>. (<year>1997</year>) <volume>11</volume>:<fpage>138</fpage>&#x2013;<lpage>46</lpage>. doi: <pub-id pub-id-type="doi">10.1037/0894-4105.11.1.138</pub-id>, <pub-id pub-id-type="pmid">9055277</pub-id></mixed-citation></ref>
<ref id="ref7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chowdhury</surname><given-names>S</given-names></name></person-group>. <article-title>The phonemic verbal fluency in progressive Supranuclear palsy (PSP) and Parkinson&#x2019;s disease (PD): relation with executive and language function measure</article-title>. <source>Neurology</source>. (<year>2018</year>) <volume>90</volume>:<fpage>82</fpage>. doi: <pub-id pub-id-type="doi">10.1212/WNL.90.15_supplement.P6.082</pub-id></mixed-citation></ref>
<ref id="ref8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reverberi</surname><given-names>C</given-names></name> <name><surname>Cherubini</surname><given-names>P</given-names></name> <name><surname>Baldinelli</surname><given-names>S</given-names></name> <name><surname>Luzzi</surname><given-names>S</given-names></name></person-group>. <article-title>Semantic fluency: cognitive basis and diagnostic performance in focal dementias and Alzheimer&#x2019;s disease</article-title>. <source>Cortex</source>. (<year>2014</year>) <volume>54</volume>:<fpage>150</fpage>&#x2013;<lpage>64</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cortex.2014.02.006</pub-id>, <pub-id pub-id-type="pmid">24681692</pub-id></mixed-citation></ref>
<ref id="ref9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farzanfar</surname><given-names>D</given-names></name> <name><surname>Statucka</surname><given-names>M</given-names></name> <name><surname>Cohn</surname><given-names>M</given-names></name></person-group>. <article-title>Automated indices of clustering and switching of semantic verbal fluency in Parkinson&#x2019;s disease</article-title>. <source>J Int Neuropsychol Soc</source>. (<year>2018</year>) <volume>24</volume>:<fpage>1047</fpage>&#x2013;<lpage>56</lpage>. doi: <pub-id pub-id-type="doi">10.1017/s1355617718000759</pub-id>, <pub-id pub-id-type="pmid">30282568</pub-id></mixed-citation></ref>
<ref id="ref10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sporns</surname><given-names>O</given-names></name></person-group>. <article-title>Graph theory methods: applications in brain networks</article-title>. <source>Dialogues Clin Neurosci</source>. (<year>2018</year>) <volume>20</volume>:<fpage>111</fpage>&#x2013;<lpage>21</lpage>. doi: <pub-id pub-id-type="doi">10.31887/DCNS.2018.20.2/osporns</pub-id>, <pub-id pub-id-type="pmid">30250388</pub-id></mixed-citation></ref>
<ref id="ref11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sporns</surname><given-names>O</given-names></name> <name><surname>Chialvo</surname><given-names>DR</given-names></name> <name><surname>Kaiser</surname><given-names>M</given-names></name> <name><surname>Hilgetag</surname><given-names>CC</given-names></name></person-group>. <article-title>Organization, development and function of complex brain networks</article-title>. <source>Trends Cogn Sci</source>. (<year>2004</year>) <volume>8</volume>:<fpage>418</fpage>&#x2013;<lpage>25</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.tics.2004.07.008</pub-id>, <pub-id pub-id-type="pmid">15350243</pub-id></mixed-citation></ref>
<ref id="ref12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>G</given-names></name> <name><surname>Ma</surname><given-names>J</given-names></name> <name><surname>Chan</surname><given-names>P</given-names></name> <name><surname>Ye</surname><given-names>Z</given-names></name></person-group>. <article-title>Graph theoretical analysis of semantic fluency in patients with Parkinson&#x2019;s disease</article-title>. <source>Behav Neurol</source>. (<year>2022</year>) <volume>2022</volume>:<fpage>6935263</fpage>. doi: <pub-id pub-id-type="doi">10.1155/2022/6935263</pub-id>, <pub-id pub-id-type="pmid">35502419</pub-id></mixed-citation></ref>
<ref id="ref13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>J</given-names></name> <name><surname>Zhang</surname><given-names>G</given-names></name> <name><surname>Sun</surname><given-names>X</given-names></name> <name><surname>Chan</surname><given-names>P</given-names></name> <name><surname>Ye</surname><given-names>Z</given-names></name></person-group>. <article-title>Smaller and denser speech graphs in nondemented patients with progressive Supranuclear palsy</article-title>. <source>Behav Neurol</source>. (<year>2023</year>) <volume>2023</volume>:<fpage>3771601</fpage>. doi: <pub-id pub-id-type="doi">10.1155/2023/3771601</pub-id>, <pub-id pub-id-type="pmid">37790602</pub-id></mixed-citation></ref>
<ref id="ref14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wenning</surname><given-names>GK</given-names></name> <name><surname>Stankovic</surname><given-names>I</given-names></name> <name><surname>Vignatelli</surname><given-names>L</given-names></name> <name><surname>Fanciulli</surname><given-names>A</given-names></name> <name><surname>Calandra-Buonaura</surname><given-names>G</given-names></name> <name><surname>Seppi</surname><given-names>K</given-names></name> <etal/></person-group>. <article-title>The Movement Disorder Society criteria for the diagnosis of multiple system atrophy</article-title>. <source>Mov Disord</source>. (<year>2022</year>) <volume>37</volume>:<fpage>1131</fpage>&#x2013;<lpage>48</lpage>. doi: <pub-id pub-id-type="doi">10.1002/mds.29005</pub-id>, <pub-id pub-id-type="pmid">35445419</pub-id></mixed-citation></ref>
<ref id="ref15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomlinson</surname><given-names>CL</given-names></name> <name><surname>Stowe</surname><given-names>R</given-names></name> <name><surname>Patel</surname><given-names>S</given-names></name> <name><surname>Rick</surname><given-names>C</given-names></name> <name><surname>Gray</surname><given-names>R</given-names></name> <name><surname>Clarke</surname><given-names>CE</given-names></name></person-group>. <article-title>Systematic review of levodopa dose equivalency reporting in Parkinson&#x2019;s disease</article-title>. <source>Mov Disord</source>. (<year>2010</year>) <volume>25</volume>:<fpage>2649</fpage>&#x2013;<lpage>53</lpage>. doi: <pub-id pub-id-type="doi">10.1002/mds.23429</pub-id>, <pub-id pub-id-type="pmid">21069833</pub-id></mixed-citation></ref>
<ref id="ref16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Postuma</surname><given-names>RB</given-names></name> <name><surname>Berg</surname><given-names>D</given-names></name> <name><surname>Stern</surname><given-names>M</given-names></name> <name><surname>Poewe</surname><given-names>W</given-names></name> <name><surname>Olanow</surname><given-names>CW</given-names></name> <name><surname>Oertel</surname><given-names>W</given-names></name> <etal/></person-group>. <article-title>MDS clinical diagnostic criteria for Parkinson&#x2019;s disease</article-title>. <source>Mov Disord</source>. (<year>2015</year>) <volume>30</volume>:<fpage>1591</fpage>&#x2013;<lpage>601</lpage>. doi: <pub-id pub-id-type="doi">10.1002/mds.26424</pub-id>, <pub-id pub-id-type="pmid">26474316</pub-id></mixed-citation></ref>
<ref id="ref17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>&#x0160;ubert</surname><given-names>M</given-names></name> <name><surname>Tykalov&#x00E1;</surname><given-names>T</given-names></name> <name><surname>Novotn&#x00FD;</surname><given-names>M</given-names></name> <name><surname>Du&#x0161;ek</surname><given-names>P</given-names></name> <name><surname>Klemp&#x00ED;&#x0159;</surname><given-names>J</given-names></name> <name><surname>Rusz</surname><given-names>J</given-names></name></person-group>. <article-title>Automated analysis of spoken language differentiates multiple system atrophy from Parkinson&#x2019;s disease</article-title>. <source>J Neurol</source>. (<year>2025</year>) <volume>272</volume>:<fpage>113</fpage>. doi: <pub-id pub-id-type="doi">10.1007/s00415-024-12828-w</pub-id>, <pub-id pub-id-type="pmid">39812820</pub-id></mixed-citation></ref>
<ref id="ref18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dietrich</surname><given-names>A</given-names></name> <name><surname>Kanso</surname><given-names>R</given-names></name></person-group>. <article-title>A review of EEG, ERP, and neuroimaging studies of creativity and insight</article-title>. <source>Psychol Bull</source>. (<year>2010</year>) <volume>136</volume>:<fpage>822</fpage>&#x2013;<lpage>48</lpage>. doi: <pub-id pub-id-type="doi">10.1037/a0019749</pub-id>, <pub-id pub-id-type="pmid">20804237</pub-id></mixed-citation></ref>
<ref id="ref19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>A</given-names></name> <name><surname>Haxby</surname><given-names>JV</given-names></name> <name><surname>Lalonde</surname><given-names>FM</given-names></name> <name><surname>Wiggs</surname><given-names>CL</given-names></name> <name><surname>Ungerleider</surname><given-names>LG</given-names></name></person-group>. <article-title>Discrete cortical regions associated with knowledge of color and knowledge of action</article-title>. <source>Science</source>. (<year>1995</year>) <volume>270</volume>:<fpage>102</fpage>&#x2013;<lpage>5</lpage>. doi: <pub-id pub-id-type="doi">10.1126/science.270.5233.102</pub-id>, <pub-id pub-id-type="pmid">7569934</pub-id></mixed-citation></ref>
<ref id="ref20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thompson-Schill</surname><given-names>SL</given-names></name> <name><surname>Jonides</surname><given-names>J</given-names></name> <name><surname>Marshuetz</surname><given-names>C</given-names></name> <name><surname>Smith</surname><given-names>EE</given-names></name> <name><surname>D&#x2019;Esposito</surname><given-names>M</given-names></name> <name><surname>Kan</surname><given-names>IP</given-names></name> <etal/></person-group>. <article-title>Effects of frontal lobe damage on interference effects in working memory</article-title>. <source>Cogn Affect Behav Neurosci</source>. (<year>2002</year>) <volume>2</volume>:<fpage>109</fpage>&#x2013;<lpage>20</lpage>. doi: <pub-id pub-id-type="doi">10.3758/CABN.2.2.109</pub-id>, <pub-id pub-id-type="pmid">12455679</pub-id></mixed-citation></ref>
<ref id="ref21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedman</surname><given-names>NP</given-names></name> <name><surname>Robbins</surname><given-names>TW</given-names></name></person-group>. <article-title>The role of prefrontal cortex in cognitive control and executive function</article-title>. <source>Neuropsychopharmacology</source>. (<year>2022</year>) <volume>47</volume>:<fpage>72</fpage>&#x2013;<lpage>89</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41386-021-01132-0</pub-id>, <pub-id pub-id-type="pmid">34408280</pub-id></mixed-citation></ref>
<ref id="ref22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watson</surname><given-names>P</given-names></name> <name><surname>Montgomery</surname><given-names>EB</given-names> <suffix>Jr</suffix></name></person-group>. <article-title>The relationship of neuronal activity within the sensori-motor region of the subthalamic nucleus to speech</article-title>. <source>Brain Lang</source>. (<year>2006</year>) <volume>97</volume>:<fpage>233</fpage>&#x2013;<lpage>40</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.bandl.2005.11.004</pub-id>, <pub-id pub-id-type="pmid">16445972</pub-id></mixed-citation></ref>
<ref id="ref23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thames</surname><given-names>AD</given-names></name> <name><surname>Foley</surname><given-names>JM</given-names></name> <name><surname>Wright</surname><given-names>MJ</given-names></name> <name><surname>Panos</surname><given-names>SE</given-names></name> <name><surname>Ettenhofer</surname><given-names>M</given-names></name> <name><surname>Ramezani</surname><given-names>A</given-names></name> <etal/></person-group>. <article-title>Basal ganglia structures differentially contribute to verbal fluency: evidence from human immunodeficiency virus (HIV)-infected adults</article-title>. <source>Neuropsychologia</source>. (<year>2012</year>) <volume>50</volume>:<fpage>390</fpage>&#x2013;<lpage>5</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.neuropsychologia.2011.12.010</pub-id>, <pub-id pub-id-type="pmid">22223078</pub-id></mixed-citation></ref>
<ref id="ref24"><label>24.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Tr&#x00F6;ster</surname><given-names>AI</given-names></name></person-group>. <article-title>Parkinson&#x2019;s disease and parkinsonism</article-title> In: <person-group person-group-type="editor"><name><surname>Brown</surname><given-names>GG</given-names></name> <name><surname>King</surname><given-names>TZ</given-names></name> <name><surname>Haaland</surname><given-names>KY</given-names></name> <name><surname>Crosson</surname><given-names>B</given-names></name></person-group>, editors. <source>APA handbook of neuropsychology: Neurobehavioral disorders and conditions: accepted science and open questions</source>. <publisher-loc>Washington, DC</publisher-loc>: <publisher-name>American Psychological Association</publisher-name> (<year>2023</year>)</mixed-citation></ref>
<ref id="ref25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>KW</given-names></name> <name><surname>Ko</surname><given-names>JH</given-names></name> <name><surname>Choi</surname><given-names>N</given-names></name> <name><surname>Jo</surname><given-names>S</given-names></name> <name><surname>Park</surname><given-names>YJ</given-names></name> <name><surname>Lee</surname><given-names>EJ</given-names></name> <etal/></person-group>. <article-title>Cortical hypometabolism associated with cognitive impairment of multiple system atrophy</article-title>. <source>Parkinsonism Relat Disord</source>. (<year>2020</year>) <volume>81</volume>:<fpage>151</fpage>&#x2013;<lpage>6</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.parkreldis.2020.10.039</pub-id>, <pub-id pub-id-type="pmid">33137618</pub-id></mixed-citation></ref>
<ref id="ref26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Righini</surname><given-names>A</given-names></name> <name><surname>Antonini</surname><given-names>A</given-names></name> <name><surname>Ferrarini</surname><given-names>M</given-names></name> <name><surname>de Notaris</surname><given-names>R</given-names></name> <name><surname>Canesi</surname><given-names>M</given-names></name> <name><surname>Triulzi</surname><given-names>F</given-names></name> <etal/></person-group>. <article-title>Thin section MR study of the basal ganglia in the differential diagnosis between striatonigral degeneration and Parkinson disease</article-title>. <source>J Comput Assist Tomogr</source>. (<year>2002</year>) <volume>26</volume>:<fpage>266</fpage>&#x2013;<lpage>71</lpage>. doi: <pub-id pub-id-type="doi">10.1097/00004728-200203000-00018</pub-id>, <pub-id pub-id-type="pmid">11884785</pub-id></mixed-citation></ref>
<ref id="ref27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boot</surname><given-names>N</given-names></name> <name><surname>Baas</surname><given-names>M</given-names></name> <name><surname>van Gaal</surname><given-names>S</given-names></name> <name><surname>Cools</surname><given-names>R</given-names></name> <name><surname>De Dreu</surname><given-names>CKW</given-names></name></person-group>. <article-title>Creative cognition and dopaminergic modulation of fronto-striatal networks: integrative review and research agenda</article-title>. <source>Neurosci Biobehav Rev</source>. (<year>2017</year>) <volume>78</volume>:<fpage>13</fpage>&#x2013;<lpage>23</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.neubiorev.2017.04.007</pub-id>, <pub-id pub-id-type="pmid">28419830</pub-id></mixed-citation></ref>
<ref id="ref28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Durstewitz</surname><given-names>D</given-names></name> <name><surname>Seamans</surname><given-names>JK</given-names></name></person-group>. <article-title>The dual-state theory of prefrontal cortex dopamine function with relevance to catechol-o-methyltransferase genotypes and schizophrenia</article-title>. <source>Biol Psychiatry</source>. (<year>2008</year>) <volume>64</volume>:<fpage>739</fpage>&#x2013;<lpage>49</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.biopsych.2008.05.015</pub-id>, <pub-id pub-id-type="pmid">18620336</pub-id></mixed-citation></ref>
<ref id="ref29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brusa</surname><given-names>L</given-names></name> <name><surname>Bassi</surname><given-names>A</given-names></name> <name><surname>Stefani</surname><given-names>A</given-names></name> <name><surname>Pierantozzi</surname><given-names>M</given-names></name> <name><surname>Peppe</surname><given-names>A</given-names></name> <name><surname>Caramia</surname><given-names>MD</given-names></name> <etal/></person-group>. <article-title>Pramipexole in comparison to l-dopa: a neuropsychological study</article-title>. <source>J Neural Transm</source>. (<year>2003</year>) <volume>110</volume>:<fpage>373</fpage>&#x2013;<lpage>80</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00702-002-0811-7</pub-id>, <pub-id pub-id-type="pmid">12658365</pub-id></mixed-citation></ref>
<ref id="ref30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subert</surname><given-names>M</given-names></name> <name><surname>Tykalova</surname><given-names>T</given-names></name> <name><surname>Novotny</surname><given-names>M</given-names></name> <name><surname>Bezdicek</surname><given-names>O</given-names></name> <name><surname>Dusek</surname><given-names>P</given-names></name> <name><surname>Rusz</surname><given-names>J</given-names></name></person-group>. <article-title>Long-term dopaminergic therapy improves spoken language in de-novo Parkinson&#x2019;s disease</article-title>. <source>J Neurol</source>. (<year>2025</year>) <volume>272</volume>:<fpage>344</fpage>. doi: <pub-id pub-id-type="doi">10.1007/s00415-025-13070-8</pub-id>, <pub-id pub-id-type="pmid">40244335</pub-id></mixed-citation></ref>
<ref id="ref31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldman-Rakic</surname><given-names>PS</given-names></name> <name><surname>Castner</surname><given-names>SA</given-names></name> <name><surname>Svensson</surname><given-names>TH</given-names></name> <name><surname>Siever</surname><given-names>LJ</given-names></name> <name><surname>Williams</surname><given-names>GV</given-names></name></person-group>. <article-title>Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction</article-title>. <source>Psychopharmacology</source>. (<year>2004</year>) <volume>174</volume>:<fpage>3</fpage>&#x2013;<lpage>16</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00213-004-1793-y</pub-id>, <pub-id pub-id-type="pmid">15118803</pub-id></mixed-citation></ref>
</ref-list>
<fn-group>
<fn fn-type="custom" custom-type="edited-by" id="fn0002">
<p>Edited by: <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/746709/overview">Maria Teresa Pellecchia</ext-link>, University of Salerno, Italy</p>
</fn>
<fn fn-type="custom" custom-type="reviewed-by" id="fn0003">
<p>Reviewed by: <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/339321/overview">Zhaohui Yao</ext-link>, Renmin Hospital of Wuhan University, China</p>
<p><ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1567924/overview">Tereza Tykalova</ext-link>, Czech Technical University in Prague, Czechia</p>
</fn>
</fn-group>
</back>
</article>